Eli Lilly and Company (LLY)
Citi resumes coverage of Eli Lily with a Buy rating: Should you invest?
Citi has resumed coverage of Eli Lilly & Co. (NYSE: LLY) with a “Buy” rating, setting a price target of $1,060 per share—implying a potential 13% upside from the current stock price.
6 Incredible Reasons to Invest in Eli Lilly
The pharma giant's financial results have been strong, largely thanks to its new crown jewel. But there may be more to come as the company's development pipeline looks incredibly exciting.
Eli Lilly Invests $1.8B To Expand Drug Output in Ireland
Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer's treatment Kisunla, which recently was approved in the U.S.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Eli Lilly invests $1.8 bln in Ireland sites to scale up Alzheimer's, obesity drug production
Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.
Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. The pharmaceutical giant is spending $1 billion to expand an existing site in Limerick Ireland, to increase the production of certain active ingredients, including those used in its Alzheimer's treatment Kisunla.
2 Weight Loss Drug Stocks Worth Stashing Away for Years
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.
Health Rounds: Once-weekly insulin from Eli Lilly appears effective as daily injections
Eli Lilly's experimental insulin that is injected just once a week is as effective as daily insulin injections for maintaining blood sugar levels in patients with type 1 or type 2 diabetes, researchers said on Tuesday at the European Association for the Study of Diabetes meeting in Madrid.
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)
Eli Lilly has been an innovative force in medicine for a long time. The company is making waves for its progress in weight loss and Alzheimer's, but there is another big reason Lilly should be on your radar.
Prediction: These 2 Companies Will Split Their Stocks by 2027
These two drugmakers have been delivering significantly above-average returns for years. Both still have excellent prospects and could decide to split their stocks as their share prices get higher.
Lilly appoints insider as finance chief amid rising investments to boost capacity
U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former CFO Anat Ashkenazi stepped down to join Google parent Alphabet.
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
Eli Lilly has three likely blockbuster drugs that are relatively new to the market. Its pipeline features three other late-stage candidates with blockbuster potential.
